Organic Active Ingredients TRIZ Cases

Selective pyrazolopyrimidine compounds suppress NLRP3 activation to lower IL-1β and IL-18 production in chronic inflammatory disorders.

Detecting both negative and positive joint pressure helps confirm intra-articular needle placement and flag effusions during injection.

Controlled polymorph forms A-D improve pyrrolopyridine stability, resist moisture uptake, and maintain solubility for reliable drug formulation.

Modified threo methylphenidate analogues reduce alpha-synuclein aggregation by enhancing Synapsin III interaction and protecting motor function.

A glycyrrhizic acid hydrogel uses water as the only solvent and no added gelators, improving wound moisture control while reducing toxicity and immune response.

Aryl tricyclic compounds overcome human STING activation limits while inducing interferon-β, cytokines, and durable tumor immunity.

Maps active proteins in situ using chemical probes and proximity oligos, preserving spatial context while detecting low-abundance enzyme activity.

An alkalinizing agent such as citrate suppresses chemotherapy-induced peripheral neuropathy, helping maintain cancer treatment with fewer neuropathic side effects.

Specific quinazoline substituent patterns tune Class I PI3K isoform inhibition to maintain therapeutic effect while limiting side effects.

Adding beta-1,3′-galactosyllactose to infant formula helps protect gut barrier function and reduce toxin-related intestinal disruption.

Mechanism-based HCM treatment uses dihydroquinazolinone compounds to modulate myosin-actin crossbridges and improve cardiac relaxation.

A high-purity Formula I composition improves CSF-1R selectivity, limiting off-target kinase toxicity while preserving stability and efficacy.

Specific crystalline RAF/MEK inhibitor forms improve stability and oral processing while preserving cancer treatment efficacy.

A stereoselective synthesis route builds high optical purity into methoxypropionic acid PPAR modulators while avoiding costly purification.

A dual-action 5-HT2A/2C inverse agonist and SERT inhibitor treats Parkinson's non-motor symptoms while limiting motor worsening.

By blocking MyD88/ERK protein interactions, these benzoimidazole derivatives suppress proliferation, trigger apoptosis, and reduce toxicity.

A sugar-linked HBV drug and IAP antagonist conjugate lowers HBsAg and HBeAg while helping avoid rebound and combination side effects.

Adjacent cis-double-bond ionizable lipids raise RNA encapsulation and transfection while enabling uniform, stable solid lipid nanoparticles.

Selective JAK kinase inhibition improves JAK-STAT pathway blocking across inflammatory and neoplastic diseases while reducing toxicity.

Patient-specific washout timing based on BMI and CYP2D6 status helps reduce serotonin syndrome risk when switching from vortioxetine to MAOIs.

Chemical structure variation in P2X3/P2X2/3 antagonists improves solubility, stability, bioavailability, and safety for receptor-mediated disease treatment.

Gas phase atomic layer deposition adds uniform inorganic shells to drug nanoparticles, limiting aggregation and extending controlled release.

Pre-activated H5-competent B. infantis internalizes HMOs and improves mucosal binding to support stable infant gut colonization.

Ginsenoside M1 is used to lower ROS, cytotoxicity, and mHtt aggregates in Huntington's disease while improving motor coordination.

Single-domain antibodies target intracellular STAT proteins to boost chemotherapy, reduce toxicity, and inhibit aberrant cell proliferation.

Small-molecule pyruvate kinase activation lowers 2,3-DPG and restores ATP balance to prolong red blood cell survival in PKD.

Biomarker-guided p38α MAPK inhibition targets tau-negative DLB to reverse synaptic dysfunction and limit neuronal loss.

Novel allosteric fused bicyclic compounds selectively inhibit mutant EGFR to address T790M and C797S resistance with lower wild-type toxicity.

Stepwise sulfonic acid, base, and hydrogenation reactions improve GDC-9545 intermediate purity and yield during scale-up.

Spatially arranged binders on polynucleotide nanostructures match antigen and immune biomarker patterns for earlier cancer detection and lower-toxicity therapy.

Broad-spectrum arsinothricin targets bacterial glutamine synthetase to treat drug-resistant infections, including tuberculosis.

Controlling pH to 5.0-6.5 with buffers and inorganic salts stabilizes delgocitinib eye drops while preserving dry eye treatment efficacy.

Esterifying levan oligosaccharides shifts prebiotic action to the small intestine, improving efficacy at lower dosages for animal feed.

Alcohol-free acetic acid myrrh extracts use polysaccharides and hydrocolloids to reduce mucosal pain and improve wound adhesion.

Targeted bicyclic heteroaryl scaffold changes improve IRAK4 inhibitor stability, bioavailability, and therapeutic index in inflammatory and cancer therapy.

Porous and rigid fillers in a ginkgo terpene lactone dropping pill speed dissolution and improve oral bioavailability for quicker absorption.

Novel sigma-2 receptor compounds protect synapses and modulate membrane trafficking to counter amyloid beta oligomer-driven cognitive decline.

Defined anhydrous forms A, B, and C use controlled crystallization to improve BTK inhibitor stability, solubility, and phase purity.

Guanidine derivatives slow factor Xa coagulation kinetics, enabling more accurate and sensitive detection of factor Xa inhibitors.

Selective HSD17B13-modulating compounds address liver disease treatment while limiting off-target inhibition across related HSD enzymes.

A modular route to KRAS G12C inhibitor intermediates improves synthesis efficiency while preserving scalable production and purification.

Specific CBD, caprylic/capric triglyceride, and alpha-tocopherol ratios maintain stability while reducing THC contamination in oral formulations.

Topical mTORC1 inhibition with rapamycin helps treat seborrheic and actinic keratosis by reducing ROS-driven senescence and improving dermal function.

Selective quinoline RET inhibitors are tuned to retain strong wild-type and V804M inhibition while improving metabolic stability and oral bioavailability.

Pyrido-pyrimidinone and pteridinone scaffolds improve selective IRE1α endoribonuclease inhibition for cancer and other IRE1-related disorders.

A charge-switching phospholipid stays non-positive at neutral pH and turns cationic in acidic compartments to improve mRNA delivery with lower cytotoxicity.

A modular Luer-Lock cannula closure seals thin prefilled syringes without adhesives, reducing contamination risk and extending storage life.

A trifluoromethylsulfonyl PROTAC degrades BCL-XL to overcome solid tumor resistance while maintaining stability, low toxicity, and in vivo activity.

Novel spirocyclic CRBN ligands address a key PROTAC bottleneck by enabling selective target protein degradation for abnormal cell proliferation.

A sodium salt crystal form resolves low water solubility and polymorphism in an S1P1 agonist while improving stability and bioavailability.